Operating executive with experience scaling technology and healthcare businesses, known for go-to-market strategy, commercial operations, and growth-stage operational rigor. Chris Lein brings senior leadership across product, sales and corporate development roles at venture-backed companies and PE portfolio firms, advising on revenue scaling, M&A readiness and KPI-driven transformation. Market-facing profile includes board advisory, interim CRO/CBO assignments, and collaboration with growth equity investors on post-investment operational plans.
Operating executive with experience scaling technology and healthcare businesses, known for go-to-market strategy, commercial operations, and growth-stage operational rigor. Chris Lein brings senior leadership across product, sales and corporate development roles at venture-backed companies and PE portfolio firms, advising on revenue scaling, M&A readiness and KPI-driven transformation. Market-facing profile includes board advisory, interim CRO/CBO assignments, and collaboration with growth equity investors on post-investment operational plans.
Advises growth-oriented investments with a hands-on, operator-led approach focused on commercial value creation in technology and healthcare. Prioritizes capital deployment toward scalable go-to-market, sales enablement and product-led revenue expansion, using KPI-driven roadmaps and short- to mid-term milestones to de-risk execution. Emphasizes M&A readiness and bolt-on consolidation as exit-enhancing levers, aligns management incentives to revenue/ARR and margin inflection, and favors disciplined stage-appropriate capital with operational playbooks to accelerate portfolio growth.
Advises growth-oriented investments with a hands-on, operator-led approach focused on commercial value creation in technology and healthcare. Prioritizes capital deployment toward scalable go-to-market, sales enablement and product-led revenue expansion, using KPI-driven roadmaps and short- to mid-term milestones to de-risk execution. Emphasizes M&A readiness and bolt-on consolidation as exit-enhancing levers, aligns management incentives to revenue/ARR and margin inflection, and favors disciplined stage-appropriate capital with operational playbooks to accelerate portfolio growth.
| Trades 494 | Longs Won 381/494 77% | Profit Factor 7.63 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $160,463.66 |
| Average Win $54,506.09 | Best Trade (Jul 17) $2.09M | Sharpe Ratio -10.45 |
| Average Loss -$24,071.66 | Worst Trade (Jul 14) -$1.35M | Z-Score 8.2 (100%) |
| Commissions $0 | Avg. Trade Length 10m 3w 2d | Expectancy $36,531.83 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 4,405 | 3,965 | 3,524 | 3,084 | 2,643 | 2,203 | 1,762 | 1,322 | 881 | 441 |